Entero Therapeutics, Inc. financial data

Symbol
ENTO on Nasdaq
Industry
Pharmaceutical Preparations
Location
777 Yamato Road, Suite 502, Boca Raton, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
First Wave BioPharma, Inc. (to 5/16/2024), AzurRx BioPharma, Inc. (to 9/14/2021), BioPharma d'Azur, Inc. (to 4/2/2014)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 447 % +266%
Debt-to-equity 128 % +6.19%
Return On Equity -106 % +83.7%
Return On Assets -14.7 % +95%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.75M shares -64.8%
Common Stock, Shares, Outstanding 4.74M shares -64.8%
Entity Public Float 6.7M USD +48.9%
Common Stock, Value, Issued 474 USD -64.8%
Weighted Average Number of Shares Outstanding, Basic 4.55M shares +1103%
Weighted Average Number of Shares Outstanding, Diluted 4.55M shares +1103%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.3M USD -39.9%
General and Administrative Expense 16.3M USD +61.3%
Operating Income (Loss) -18.6M USD -33.5%
Nonoperating Income (Expense) -80.7K USD +95.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.9M USD +44.8%
Income Tax Expense (Benefit) 4.26M USD
Net Income (Loss) Attributable to Parent -9.92M USD +36.7%
Earnings Per Share, Basic 34.2 USD/shares +93.6%
Earnings Per Share, Diluted 31.5 USD/shares +93.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 367K USD -88.9%
Accounts Receivable, after Allowance for Credit Loss, Current 20K USD -28.7%
Assets, Current 83.8M USD +2008%
Property, Plant and Equipment, Net 1.34K USD -95.4%
Operating Lease, Right-of-Use Asset 144K USD -31.8%
Intangible Assets, Net (Excluding Goodwill) 63.4M USD
Goodwill 1.68M USD 0%
Assets 85.8M USD +1348%
Accounts Payable, Current 2.21M USD +282%
Accrued Liabilities, Current 219K USD -73.7%
Liabilities, Current 15.7M USD +532%
Deferred Income Tax Liabilities, Net 571K USD
Operating Lease, Liability, Noncurrent 80.2K USD -51.7%
Other Liabilities, Noncurrent 3.85M USD +58528%
Liabilities 15.8M USD +495%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.45M USD -14.8%
Retained Earnings (Accumulated Deficit) -190M USD -5.51%
Stockholders' Equity Attributable to Parent 8.37M USD +155%
Liabilities and Equity 85.8M USD +1348%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.75M USD -31.7%
Net Cash Provided by (Used in) Financing Activities 3.38M USD -4.74%
Net Cash Provided by (Used in) Investing Activities 88.2K USD
Common Stock, Shares Authorized 100M shares +100%
Common Stock, Shares, Issued 4.74M shares -64.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Interest Paid, Excluding Capitalized Interest, Operating Activities 22K USD +144%
Deferred Tax Assets, Valuation Allowance 33.4M USD +13.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 1.6 pure
Deferred Tax Assets, Gross 33.5M USD +13.4%
Operating Lease, Liability 160K USD -31%
Depreciation 22K USD -85.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.8M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid 171K USD -38.4%
Property, Plant and Equipment, Gross 87.8K USD 0%
Operating Lease, Liability, Current 79.5K USD +21.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60.6K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 88.8K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.5K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 60.6K USD -31.8%
Deferred Tax Assets, Operating Loss Carryforwards 23.1M USD +22%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 60.6K USD -31.8%
Additional Paid in Capital 199M USD +8.18%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 34K USD +17.1%
Deferred Tax Assets, Net of Valuation Allowance 48K USD -25%
Share-based Payment Arrangement, Expense 708K USD -29.2%
Interest Expense 79.7K USD +314%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%